Videos

Experts in the management of diffuse large B-cell lymphoma (DLBCL) discuss the use of novel CD19-antibody mono- and combination therapies to treat relapsed/refractory subpopulations.

Suresh S. Ramalingam, MD, discusses the phase III FLAURA trial.

Aditya Bardia, MD, MPH, discusses the efficacy of sacituzumab govitecan in patients with triple-negative breast cancer.

Jennifer Woyach, MD, discusses the adverse events that differentiate the toxicity profiles of the treatments that are available in the frontline setting for patients with chronic lymphocytic leukemia.

Rogerio C. Lilenbaum, MD, discusses molecular panels and other testing for patients with nonsquamous non-small cell lung cancer.

Nizar Bahlis, MD, discusses the findings from the randomized phase III MAIA trial, which evaluated the combination regimen of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in transplant-ineligible patients with multiple myeloma.

Amir Khan, MD, discusses the possible reasons for the rising incidence of young adult patients with gastric cancer and colorectal cancer at the 2020 Gastrointestinal Cancers Symposium.

Cathy Eng, MD, FACP, FASCO, reviews the case of a 68-year-old diagnosed with metastatic NTRK fusion-positive colon cancer and shares treatments options.

Rajneesh Nath, MD, discusses the early results of the phase III SIERRA trial investigating the efficacy of Iomab-B and protocol-specified allogeneic hematopoietic stem cell transplant versus the standard of care in older patients with active, relapsed or refractory acute myeloid leukemia.

Jae Park, MD, discusses his key takeaways from chimeric antigen receptor T cells in the treatment landscape of patients with acute lymphoblastic leukemia.

Linda Bosserman, MD, discusses the emerging role of telehealth and the challenges with implementing this type of care into cancer centers in the United States.